Shionogi to Partner with ALS/MND Natural History Consortium to Collect Real-World Data in ALS, Reinforcing Investments in ALS Research
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter, “Shionogi”) today announced its continued partnership with the ALS/MND Natural History Consortium (Consortium) to collect real-world data in amyotrophic lateral sclerosis (ALS).
The goal of this collaboration is to deepen scientific knowledge of ALS through access to real-world data, including data of approved therapies for ALS, such as RADICAVA ORS® (edaravone). By collaborating with the Consortium, Shionogi is contributing to a broader understanding of ALS as well as the therapeutic effects of currently approved treatments.
“A major scientific challenge in ALS is determining how the disease presents and evolves across diverse patient populations in real-world settings. Access to real-world data is critical to addressing this complexity,” said Gustavo A. Suarez Zambrano, M.D., Vice President, Medical Affairs, Rare Disease, Shionogi Inc. “This partnership will advance our knowledge of ALS and help improve care for people living with the disease, reinforcing Shionogi’s deep commitment to research in the ALS community.”
